Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Movetis announces today that Credit Suisse and KBC Securities, acting as Joint Global Coordinators and on behalf of the bank syndicate, have fully exercised the Over-allotment Option, in accordance with provisions contained in the initial public offering (IPO) prospectus.
At the IPO a total of 7,979,592 shares were allotted, of which 6,938,776 were new shares and 1,040,816 were over-allotment shares.
The full exercise of the Over-allotment Option will result in 1,040,816 new shares (without VVPR Strip) being issued by Movetis NV at the offer price of €12.25 per share, amounting to approximately 15% of the offering (before over-allotments and exercise of the Over-allotment Option). No stabilisation transactions have taken place
As a result, a total of 7,979,592 new shares of Movetis NV will have been placed on the market, equal to approximately 37.9% of the share capital of Movetis NV (after exercise of the Over-allotment Option), represented by 21,035,175 shares.
Transfer and payment of shares related to the Over-allotment Option has taken place on 21 December, 2009, at the offering price.
Movetis NV has now raised a gross amount of €97.75 million in its IPO: €85 million from the placement of new shares in the framework of the IPO and €12.75 million from the issue of new shares in connection with the exercise of the Over-allotment Option.
In accordance with Article15 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), Movetis also announces that the share capital of Movetis amounts to EUR 52,567,221.48, represented by 21,035,175 shares (the denominator). The total amount paid up on the shares (capital and issue premium) since incorporation amounts to EUR 160,431,002.
Movetis has an aggregate of 9,460,532 outstanding warrants, whereby six warrants give the right to subscribe for one share. Thus, the aggregate number of shares and voting rights that can be obtained upon exercise of the outstanding warrants when vested amounts to 1,576,755.
Movetis NV has not issued any other rights to subscribe for voting securities that have not yet been issued or any shares with voting rights.
The voting securities of Movetis NV are not divided into categories.
The Articles of Association of Movetis NV do not provide for an additional notification threshold.
Tags: stock market